Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1955 1
1956 2
1957 4
1958 1
1962 2
1963 6
1964 2
1965 2
1966 2
1967 1
1968 2
1970 5
1971 2
1972 1
1975 1
1976 2
1977 1
1979 1
1981 3
1982 5
1983 5
1984 1
1985 5
1986 10
1987 10
1988 5
1989 11
1990 14
1991 10
1992 13
1993 5
1994 14
1995 21
1996 13
1997 19
1998 17
1999 16
2000 26
2001 22
2002 21
2003 28
2004 22
2005 38
2006 44
2007 33
2008 28
2009 33
2010 42
2011 54
2012 60
2013 53
2014 59
2015 48
2016 70
2017 70
2018 54
2019 52
2020 57
2021 60
2022 47
2023 37
2024 30
2025 42
2026 25

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,262 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean fujimoto n[au] (1,242 results)?
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, Saito K, Kawaguchi Y, Kamio T, Kojima A, Sugihara M, Yamaguchi K; DESTINY-Gastric01 Investigators. Shitara K, et al. Among authors: sugimoto n. N Engl J Med. 2020 Jun 18;382(25):2419-2430. doi: 10.1056/NEJMoa2004413. Epub 2020 May 29. N Engl J Med. 2020. PMID: 32469182 Clinical Trial.
Turbulence Activates Platelet Biogenesis to Enable Clinical Scale Ex Vivo Production.
Ito Y, Nakamura S, Sugimoto N, Shigemori T, Kato Y, Ohno M, Sakuma S, Ito K, Kumon H, Hirose H, Okamoto H, Nogawa M, Iwasaki M, Kihara S, Fujio K, Matsumoto T, Higashi N, Hashimoto K, Sawaguchi A, Harimoto KI, Nakagawa M, Yamamoto T, Handa M, Watanabe N, Nishi E, Arai F, Nishimura S, Eto K. Ito Y, et al. Among authors: sugimoto n. Cell. 2018 Jul 26;174(3):636-648.e18. doi: 10.1016/j.cell.2018.06.011. Epub 2018 Jul 12. Cell. 2018. PMID: 30017246 Free article.
Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial.
Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Sakamoto Y, Nishina T, Inaki K, Kuwahara Y, Wada N, Suto F, Arita T, Sugihara M, Tsuchihashi Z, Saito K, Kojima A, Yamaguchi K. Shitara K, et al. Among authors: sugimoto n. Nat Med. 2024 Jul;30(7):1933-1942. doi: 10.1038/s41591-024-02992-x. Epub 2024 May 14. Nat Med. 2024. PMID: 38745009 Free PMC article. Clinical Trial.
Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial.
Yamaguchi K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, Shimoyama T, Lee KW, Saito K, Kawaguchi Y, Kamio T, Kojima A, Sugihara M, Shitara K. Yamaguchi K, et al. Among authors: sugimoto n. J Clin Oncol. 2023 Feb 1;41(4):816-825. doi: 10.1200/JCO.22.00575. Epub 2022 Nov 15. J Clin Oncol. 2023. PMID: 36379002 Free PMC article. Clinical Trial.
Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer.
Kawakami H, Kadowaki S, Makiyama A, Tsuda M, Hirata K, Sugimoto N, Machida N, Hara H, Hirano H, Esaki T, Komatsu Y, Hironaka S, Kobayashi Y, Kakimi K, Chiba Y, Boku N, Hyodo I, Muro K. Kawakami H, et al. Among authors: sugimoto n. J Clin Oncol. 2025 Jul;43(19):2184-2195. doi: 10.1200/JCO-24-02463. Epub 2025 May 16. J Clin Oncol. 2025. PMID: 40378356 Clinical Trial.
ONO-4578 Plus Nivolumab in Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer.
Kawazoe A, Yamaguchi K, Hamaguchi T, Narita Y, Boku S, Oshima T, Hara H, Hamamoto Y, Ishido K, Esaki T, Hosaka H, Yasui H, Koeda K, Nishina T, Tsuji Y, Fukagawa T, Goto M, Oki E, Sugimoto N, Matsuoka H, Yokoyama F, Yoshida T, Yoshida K, Oshima Y, Iwasa S. Kawazoe A, et al. Among authors: sugimoto n. Cancer Sci. 2025 Sep;116(9):2523-2536. doi: 10.1111/cas.70130. Epub 2025 Jul 6. Cancer Sci. 2025. PMID: 40618725 Free PMC article. Clinical Trial.
Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study).
Kawakami H, Nakanishi K, Makiyama A, Konishi H, Morita S, Narita Y, Sugimoto N, Minashi K, Imano M, Inamoto R, Kodera Y, Kume H, Yamaguchi K, Hashimoto W, Muro K; EN-DEAVOR Study Group. Kawakami H, et al. Among authors: sugimoto n. Gastric Cancer. 2025 Jan;28(1):51-61. doi: 10.1007/s10120-024-01555-w. Epub 2024 Oct 10. Gastric Cancer. 2025. PMID: 39387986 Free PMC article.
First-line pembrolizumab plus chemotherapy for participants in Japan with gastric or gastroesophageal junction adenocarcinoma: subgroup analysis of the phase 3 KEYNOTE-859 study.
Yasui H, Aizawa M, Yamaguchi K, Kawazoe A, Hara H, Tsuda M, Shoji H, Sugimoto N, Shibata N, Amagai K, Choda Y, Iwagami S, Esaki T, Kadowaki S, Shiratori S, Han S, Bordia S, Shitara K. Yasui H, et al. Among authors: sugimoto n. Int J Clin Oncol. 2025 Oct;30(10):2003-2011. doi: 10.1007/s10147-025-02847-6. Epub 2025 Aug 1. Int J Clin Oncol. 2025. PMID: 40750941 Clinical Trial.
1,262 results